Home・Akciju saraksts・Beam Therapeutics Inc

Beam Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

26.92 -4.71

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

26.6

Max

28.42

Galvenie mērījumi
By Trading Economics
Ienākumi	-339M -94M
Pārdošana	-82M 32M
EPS	-0.91
Peļņas marža	-297.177
Darbinieki	522
EBITDA	-349M -89M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+87.9% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 2. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-425M 2.7B
Iepriekšējā atvēršanas cena	31.63
Iepriekšējā slēgšanas cena	26.92

Ziņu noskaņojums

By Acuity

86%

14%

320 / 340 Rangs Healthcare

Beam Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. aug. 23:06 UTC

Beam Therapeutics Inc. shares are lower in after-market hours, following a session low shortly after the open, despite three consecutive higher daily closes.

2026. g. 3. aug. 19:16 UTC

Correlated Moves

News

Beam Therapeutics is rising amid a broader market rally, with a market cap of $2.64 billion and $1.2 billion in liquidity to support operations.

2026. g. 31. jūl. 19:16 UTC

Correlated Moves

Beam Therapeutics shares are lower, reflecting a decline in first-quarter results and broader sector weakness. The stock remains near the lower end of its one-month range.

2026. g. 30. jūl. 23:06 UTC

Beam Therapeutics Inc shares are higher in after-hours trading, advancing since Thursday's close, despite remaining below the 20-day moving average.

2026. g. 29. jūl. 22:51 UTC

Beam Therapeutics shares are lower in after-market hours following a volatile session, amid broader market uncertainty after the Federal Reserve's interest rate decision.

2026. g. 28. jūl. 23:51 UTC

Beam Therapeutics Inc shares are lower in after-market trading, experiencing unusual volatility amid broader market declines and positioned below its 20-day moving average.

2026. g. 27. jūl. 23:06 UTC

Beam Therapeutics Inc shares are higher in after-market hours, despite a broader decline in trading. No specific news was identified to explain the increase.

2026. g. 24. jūl. 19:26 UTC

Event

Correlated Moves

Beam Therapeutics is declining today, reflecting broader market trends, with the Russell 2000 Index down. The stock remains below its 20-day moving average.

2026. g. 23. jūl. 09:51 UTC

News

Beam Therapeutics is higher in pre-market trading, driven by significant upcoming clinical milestones, including the global BEAM-302 trial and an FDA application for risto-cel.

2026. g. 22. jūl. 23:46 UTC

Beam Therapeutics shares higher in after-market trading, advancing since Wednesday's close. The stock remains below its 20-day moving average amid broader market influences.

2026. g. 21. jūl. 18:06 UTC

Correlated Moves

Beam Therapeutics shares are higher today, reflecting positive sentiment in small-cap stocks amid anticipation of upcoming earnings results from major companies.

2026. g. 20. jūl. 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

Salīdzinājums

Cenas izmaiņa

Beam Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

87.9% augšup

Prognoze 12 mēnešiem

Vidējais 53.27 USD 87.9%

Augstākais 80 USD

Zemākais 26 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Beam Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Beam Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

320 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.